Your Messages Inbox
Your Article Summary
See Latest ArticlesSepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics
Sepracor, 07/02/09
Sepracor Inc. announced that it has completed the analysis and validation of the preliminary results of a Phase II, 514-patient study evaluating the efficacy and safety of SEP-225289 for the treatment of Major Depressive Disorder, including patients with melancholic and atypical features. Sepracor determined that SEP-225289 did not meet the primary efficacy endpoint, which was a reduction in symptoms of depression following eight weeks of treatment, as assessed using the clinician-rated, 17-item HAM-D scale. The positive control in the study did achieve separation from placebo that was statistically significant on the primary endpoint.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/08/09
Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial
Nephrology Dialysis Transplantation, 12/08/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Cerner Enters R&D Pact with University
HealthDataManagement, 12/08/09
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma
Bristol Myers-Squibb Company, 12/08/09
Article Search
Sponsor